Evidence map›Paper›PMID 33144484›Full record

ArticleIn vivo (Athens, Greece)

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers.

Anand Sharma, Deshveer S Babra, Priya V Joshi, Marcia Hall, Andrew Gogbashian, Nikhil Vasdev, Magdalene Joseph, Amir Yazdan, Edward Kanfer

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Anand SharmaDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K. anand.sharma3@nhs.net.
Deshveer S BabraDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Priya V JoshiDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Marcia HallDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Andrew GogbashianDepartment of Radiology, Paul Strickland Scanner Centre, London, U.K.
Nikhil VasdevDepartment of Urology and Surgery, Lister Hospital, East and North Herts NHS Trust, Stevenage, U.K.
Magdalene JosephDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Amir YazdanDepartment of Medical Oncology, Mount Vernon Cancer Centre, London, U.K.
Edward KanferDepartment of Haematology, Hammersmith Hospital, Imperial College Healthcare Trust, London, U.K.
Mount Vernon Cancer Centre · GBEast and North Hertfordshire NHS Trust · GBImperial College Healthcare NHS Trust · GBUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimHigh-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. PATIENTS AND

methodsTwenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes.

resultsMedian age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2

conclusionIn relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoplasms, Germ Cell and EmbryonalAdultCarboplatinFemaleHumansMalePrognosisSalvage TherapyStem Cell TransplantationCarboplatinhigh dose chemotherapyRelapsed germ cell cancerstem cell transplantsurvival

Identifiers

PMID33144484
PMCPMC7811657
OpenAlexW3096526776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.